NMPA’s CDE Prioritizes Marketing Filings for Innovative Drugs with Priority Review Status
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) released a...
Fineline Cube
Wantai Biological’s P85 Ab Detection Kit Receives NMPA Approval for Nasopharyngeal Carcinoma Screening
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a Chinese pharmaceutical company, announced last...
Chinese ADCs from Escugen, Hansoh, and MediLink Therapeutics Eye Breakthrough Designations in China
The Center for Drug Evaluation of the National Medical Products Administration (NMPA) has indicated on...
GSK Commits USD 800 Million to New State-of-the-Art Manufacturing Facility in Pennsylvania
GSK plc (NYSE: GSK), a leading UK pharmaceutical company, has announced a significant investment in...
ImmuneOnco Biopharmaceuticals Partners with Yangtze River Pharmaceutical to Boost Pipeline Development
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a biopharmaceutical company based in China, has entered...
LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS
LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the reclamation of control...
Zhuhai Beihai Biotech’s Beizary Receives FDA Clearance for Multiple Cancer Indications
Zhuhai Beihai Biotech Co., Ltd has announced that it has received marketing clearance from the...
BeiGene’s PD-1 Inhibitor Tevimbra Scores First US Prescription, Offers More Affordable Option
BeiGene Ltd, a leading China-based biotechnology company (NASDAQ: BGNE; HKG: 6160; SHA: 688235), has announced...
RemeGen’s Telitacicept Receives Priority Review Status from China’s CDE for gMG Treatment
RemeGen (HKG: 9995), a China-based pharmaceutical company, has announced that the Center for Drug Evaluation...
China’s Pharmaceutical Trade Reaches USD 147.491 Billion in First Three Quarters, Export Growth Outpaces Imports
The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...
RemeGen’s Taitaxipu Receives CDE Acceptance for New Indication Application in China
RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) has announced that the Center for Drug Evaluation...
Shanghai MicroPort Initiates Pre-Marketing Clinical Study for Embolic Microspheres in Liver Cancer Treatment
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese medical technology company, has announced...
Chongqing Zhifei Biological’s Influenza Vaccine Application Accepted by China’s Drug Evaluation Center
On October 24, 2024, the Center for Drug Evaluation of the National Medical Products Administration...
TheDerma’s Series A+ Round to Fund R&D and Commercialization of AhR Targeted Drugs
TheDerma, a Shanghai-based pharmaceutical company, has announced the completion of a nearly CNY 100 million...
Jiangxi Province to Implement Direct Medical Insurance Fund Payments for NRDL Drugs from December 2024
The Jiangxi Province Healthcare Security Administration and the Jiangxi Provincial Department of Finance have jointly...
BMS Launches Cardiac Myosin Inhibitor Camzyos in China for Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the official market launch of its cardiac myosin...
Boston Scientific Reports 19.5% YOY Increase in Q3 Net Sales, Driven by New Product Launches and Market Expansion
Boston Scientific Corporation (NYSE: BSX), a leading medical device manufacturer in the U.S., has announced...
Hengrui Pharmaceuticals Considers HKEX Secondary Listing Amid Financing Challenges in Mainland China
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, is reportedly planning...
Everest Medicines’ Velsipity Approved for Use in Select Hospitals in China’s Greater Bay Area
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received approval...
Daiichi Sankyo’s Pexidartinib Poised for Priority Review in China for TGCT Treatment
The official website of the Center for Drug Evaluation (CDE) under China’s National Medical Products...